Naganna N - Search Results

1

Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.

Opoku-Temeng C , Dayal N , Hernandez DE , Naganna N , Sintim HO . Opoku-Temeng C , et al. Among authors: naganna n. Chem Commun (Camb). 2018 May 1;54(36):4521-4524. doi: 10.1039/c8cc01154k. Chem Commun (Camb). 2018. PMID: 29629444

2

Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Larocque E, Naganna N, Ma X, Opoku-Temeng C, Carter-Cooper B, Chopra G, Lapidus RG, Sintim HO. Larocque E, et al. Among authors: naganna n. Future Med Chem. 2017 Jul;9(11):1213-1225. doi: 10.4155/fmc-2017-0067. Epub 2017 May 11. Future Med Chem. 2017. PMID: 28490193 Free PMC article.

3

Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.

Larocque EA, Naganna N, Opoku-Temeng C, Lambrecht AM, Sintim HO. Larocque EA, et al. Among authors: naganna n. ChemMedChem. 2018 Jun 20;13(12):1172-1180. doi: 10.1002/cmdc.201700829. Epub 2018 May 22. ChemMedChem. 2018. PMID: 29608815 Free PMC article.

4

Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.

Naganna N, Opoku-Temeng C, Choi EY, Larocque E, Chang ET, Carter-Cooper BA, Wang M, Torregrosa-Allen SE, Elzey BD, Lapidus RG, Sintim HO. Naganna N, et al. EBioMedicine. 2019 Feb;40:231-239. doi: 10.1016/j.ebiom.2019.01.012. Epub 2019 Jan 25. EBioMedicine. 2019. PMID: 30686755 Free PMC article.

5

Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.

Wang M, Naganna N, Sintim HO. Wang M, et al. Among authors: naganna n. Bioorg Chem. 2019 Sep;90:103052. doi: 10.1016/j.bioorg.2019.103052. Epub 2019 Jun 8. Bioorg Chem. 2019. PMID: 31226468

6

Isoquinoline Antimicrobial Agent: Activity against Intracellular Bacteria and Effect on Global Bacterial Proteome.

Karanja CW, Naganna N, Abutaleb NS, Dayal N, Onyedibe KI, Aryal U, Seleem MN, Sintim HO. Karanja CW, et al. Among authors: naganna n. Molecules. 2022 Aug 10;27(16):5085. doi: 10.3390/molecules27165085. Molecules. 2022. PMID: 36014324 Free PMC article.

7

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.

Khatri U, Dayal N, Hu X, Larocque E, Naganna N, Shen T, Liu X, Holtsberg FW, Aman MJ, Sintim HO, Wu J. Khatri U, et al. Among authors: naganna n. Mol Cancer Ther. 2023 Jun 1;22(6):717-725. doi: 10.1158/1535-7163.MCT-22-0629. Mol Cancer Ther. 2023. PMID: 37070927 Free PMC article.

8

Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds.

Larocque E, Chu EFY, Naganna N, Sintim HO. Larocque E, et al. Among authors: naganna n. ACS Omega. 2020 Feb 4;5(6):2690-2698. doi: 10.1021/acsomega.9b03223. eCollection 2020 Feb 18. ACS Omega. 2020. PMID: 32095692 Free PMC article.

9

A rink-amide soluble support: high purity conotoxins and other peptides accessed with minimal reagents.

Bisht B, Naganna N, Madhavan N. Bisht B, et al. Among authors: naganna n. Org Biomol Chem. 2019 Aug 14;17(30):7238-7246. doi: 10.1039/c9ob01214a. Epub 2019 Jul 22. Org Biomol Chem. 2019. PMID: 31328741

10

Soluble non-cross-linked poly(norbornene) supports for peptide synthesis with minimal reagents.

Naganna N, Madhavan N. Naganna N, et al. J Org Chem. 2014 Dec 5;79(23):11549-57. doi: 10.1021/jo502197n. Epub 2014 Nov 12. J Org Chem. 2014. PMID: 25372408

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters